Real-world data analysis in patients with EGFR-mutated stage III non-small cell lung cancer (NSCLC): Radiochemotherapy and osimertinib as the new standard

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038595

Enrollment

Registered

2025-12-09

Start date

2025-01-27

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (locally advanced) with EGFR mutation

Interventions

Group 1: Treatment cohort: Treatment without adjuvant Osimertinib (2015-2030), Progression free survival (10-60 months), overall survival, side effects to normal tissue, CTC-AE Group 2: Treatment coh

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: NSCLC, radiotherapy (curative), EGFR mutation (classical): exon 19 deletion (Ex19del) or exon 21 L858R point mutation

Exclusion criteria

Exclusion criteria: age < 18 years, no mutation in the relevant exons

Design outcomes

Primary

Measure	Time frame
Progression free survival (10-60 months)	—

Secondary

Measure	Time frame
overall survival, side effects to normal tissue, CTC-AE	—

Countries

Germany

Contacts

Public ContactMaja Guberina

Klinik und Poliklinik für Strahlentherapie

maja.guberina@uk-essen.de0201 723 2322

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026